OTCMKTS:WILYY - DEMANT A S/ADR Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $16.95 0.00 (0.00 %) (As of 05/21/2019 04:00 PM ET)Previous Close$16.95Today's Range$16.95 - $16.9552-Week Range$14.20 - $23.90VolumeN/AAverage Volume270 shsMarket Capitalization$8.31 billionP/E Ratio29.22Dividend YieldN/ABeta0.73 ProfileAnalyst RatingsChartHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Demant A/S, a hearing healthcare company, develops, manufactures, and sells products and equipment to enhance people's hearing in Europe, North America, the Pacific, Asia, and internationally. Its products include hearing devices and implants; diagnostic instruments; and personal communication systems, such as headsets and solutions for the professional call center and office market, as well as consumer headsets for the gaming and mobile segments. The company was formerly known as William Demant Holding A/S and changed its name to Demant A/S in March 2019. Demant A/S was founded in 1904 and is headquartered in Smørum, Denmark. Receive WILYY News and Ratings via Email Sign-up to receive the latest news and ratings for WILYY and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Surgical appliances & supplies Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:WILYY Previous SymbolNASDAQ:WILYY CUSIPN/A CIKN/A Webhttp://www.demant.com/ Phone45-3917-7300Debt Debt-to-Equity Ratio0.31 Current Ratio0.80 Quick Ratio0.58Price-To-Earnings Trailing P/E Ratio29.22 Forward P/E Ratio25.68 P/E Growth2.14 Sales & Book Value Annual Sales$2.21 billion Price / Sales3.77 Cash Flow$0.5890 per share Price / Cash Flow28.78 Book Value$2.28 per share Price / Book7.43Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees14,614 Outstanding Shares490,440,000Market Cap$8.31 billion Next Earnings Date5/21/2019 (Estimated) OptionableNot Optionable DEMANT A S/ADR (OTCMKTS:WILYY) Frequently Asked Questions What is DEMANT A S/ADR's stock symbol? DEMANT A S/ADR trades on the OTCMKTS under the ticker symbol "WILYY." When is DEMANT A S/ADR's next earnings date? DEMANT A S/ADR is scheduled to release their next quarterly earnings announcement on Tuesday, May 21st 2019. View Earnings Estimates for DEMANT A S/ADR. Has DEMANT A S/ADR been receiving favorable news coverage? Headlines about WILYY stock have trended somewhat negative this week, InfoTrie Sentiment reports. The research group scores the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. DEMANT A S/ADR earned a coverage optimism score of -1.2 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the next several days. Who are some of DEMANT A S/ADR's key competitors? Some companies that are related to DEMANT A S/ADR include Align Technology (ALGN), Zimmer Biomet (ZBH), COLOPLAST A/S/ADR (CLPBY), Smith & Nephew (SNN), Steris (STE), MSA Safety (MSA), Wright Medical Group (WMGI), Avanos Medical (AVNS), Inogen (INGN), Wound Management Technologies (WNDM), Establishment Labs (ESTA), RTI Surgical (RTIX), ConforMIS (CFMS), Invacare (IVC) and Sientra (SIEN). What other stocks do shareholders of DEMANT A S/ADR own? Based on aggregate information from My MarketBeat watchlists, some companies that other DEMANT A S/ADR investors own include Acacia Communications (ACIA), Gentex (GNTX), Pacific Biosciences of California (PACB), Tractor Supply (TSCO), Core Laboratories (CLB), Johnson & Johnson (JNJ), Akamai Technologies (AKAM), Plus500 (PLUS), Kingfisher (KGF) and IMI (IMI). Who are DEMANT A S/ADR's key executives? DEMANT A S/ADR's management team includes the folowing people: Mr. Søren Nielsen, CEO, Pres & Member of Exec. Board (Age 49)Mr. René Schneider, CFO & Member of Exec. Board (Age 46)Mr. Søren Bergholt Andersson, VP of Investor Relations (Age 42)Ms. Trine Kromann-Mikkelsen, VP of Corp. Communication & RelationsMr. Jes Olsen, Pres of Oticon Medical How do I buy shares of DEMANT A S/ADR? Shares of WILYY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is DEMANT A S/ADR's stock price today? One share of WILYY stock can currently be purchased for approximately $16.95. How big of a company is DEMANT A S/ADR? DEMANT A S/ADR has a market capitalization of $8.31 billion and generates $2.21 billion in revenue each year. The company earns $288.76 million in net income (profit) each year or $0.58 on an earnings per share basis. DEMANT A S/ADR employs 14,614 workers across the globe. What is DEMANT A S/ADR's official website? The official website for DEMANT A S/ADR is http://www.demant.com/. How can I contact DEMANT A S/ADR? DEMANT A S/ADR's mailing address is Kongebakken 9, Smorum G7, 2765. The company can be reached via phone at 45-3917-7300 or via email at [email protected] MarketBeat Community Rating for DEMANT A S/ADR (OTCMKTS WILYY)Community Ranking: 2.0 out of 5 ( )Outperform Votes: 144 (Vote Outperform)Underperform Votes: 209 (Vote Underperform)Total Votes: 353MarketBeat's community ratings are surveys of what our community members think about DEMANT A S/ADR and other stocks. Vote "Outperform" if you believe WILYY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe WILYY will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/21/2019 by MarketBeat.com StaffFeatured Article: What is a capital gain? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.